Drug Profile
TD 0714
Alternative Names: TD0714Latest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Theravance Biopharma
- Class Antihypertensives; Cardiovascular therapies
- Mechanism of Action Neprilysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Kidney disorders
Most Recent Events
- 22 Feb 2023 Discontinued - Phase-I for Cardiovascular disorders (In volunteers) in USA (unspecified route)(Theravance Biopharma pipeline, February 2023)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in USA (Capsule)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Kidney-disorders(In volunteers) in USA (Capsule)(Theravance Biopharma pipeline, February 2023)